Cite

Author response for 'Findings for <scp>iGlarLixi</scp> vs <scp>BIAsp</scp> 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics'

MLA

null Philip D. Home, et al. Author Response for “Findings for iGlarLixi vs BIAsp 30 Confirmed in Groups of People with Type 2 Diabetes with Different Biomedical Characteristics.” Oct. 2022. EBSCOhost, https://doi.org/10.1111/dom.14907/v2/response1.



APA

null Philip D. Home, null Rory J. McCrimmon, null Julio Rosenstock, null Matthias Blüher, null Katrin Pegelow, null Lydie Melas‐Melt, null Khier Djaballah, null Francesco Giorgino, & null the SoliMix trial investigators. (2022). Author response for “Findings for iGlarLixi vs BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.” https://doi.org/10.1111/dom.14907/v2/response1



Chicago

null Philip D. Home, null Rory J. McCrimmon, null Julio Rosenstock, null Matthias Blüher, null Katrin Pegelow, null Lydie Melas‐Melt, null Khier Djaballah, null Francesco Giorgino, and null the SoliMix trial investigators. 2022. “Author Response for ‘Findings for iGlarLixi vs BIAsp 30 Confirmed in Groups of People with Type 2 Diabetes with Different Biomedical Characteristics,’” October. doi:10.1111/dom.14907/v2/response1.